Of note, our immunotherapeutic approach using rSmeg-hMIF-hIL-7 showed an enhanced anticancer effect with one of the ICI drugs, anti-PD-L1 treatment, in a tumor-bearing mouse model (figure 6), suggesting its further feasibility in cancer treatment. Here, CD274 is linked to neoplasm.